Provenienza dei contatti di primo grado di Emma Meurling
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Public Company | Biotechnology | 19 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Emma Meurling tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
ONCOLYTICS BIOTECH INC. | Biotechnology | Director/Board Member Director/Board Member | |
Nyenrode Business Universiteit | College/University | Graduate Degree | |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
Van Herk Investments BV
Van Herk Investments BV Investment ManagersFinance Van Herk Investments BV (VHI) is the private equity investment arm of the Van Herk Groep BV, based in Rotterdam. The parent firm was established in the 1950s as a family business with a focus on real estate investments. VHI invests in listed and unlisted firms across diverse sectors primarily in The Netherlands. | Investment Managers | Director of Finance/CFO | |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Maryland | College/University | Undergraduate Degree | |
The University of California, San Francisco | College/University | Corporate Officer/Principal | |
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Medical/Nursing Services | Director/Board Member | |
University of Lund | College/University | Undergraduate Degree Masters Business Admin | |
Erasmus University Rotterdam | College/University | Undergraduate Degree | |
Université Paris 1 Panthéon-Sorbonne | College/University | Doctorate Degree | |
Van Herk Groep BV
Van Herk Groep BV Financial ConglomeratesFinance Van Herk Groep BV provides investment services to the real estate, energy, and life science sectors. The company was founded by Aat van Herk and is headquartered in Rotterdam, the Netherlands. | Financial Conglomerates | Director of Finance/CFO | |
Max-Planck-Institute for Molecular Genetics | College/University | Doctorate Degree | |
University of Bielefeld | College/University | Doctorate Degree | |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Apposite Capital LLP
Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
IMMUNE DESIGN CORP | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Immunexpress Pty Ltd.
Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Medical Specialties | Director/Board Member | |
Uni Targeting Research AS
Uni Targeting Research AS BiotechnologyHealth Technology Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway. | Biotechnology | Director/Board Member | |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Chief Executive Officer | |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Director of Investments | |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member | |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | Miscellaneous Commercial Services | Director/Board Member | |
Swedish Securities Dealers Association | Director/Board Member | ||
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | Pharmaceuticals: Major | Director/Board Member | |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member | |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Biotechnology | Director/Board Member | |
Universidad del Rosario | College/University | Doctorate Degree | |
MENDUS AB | Biotechnology | Director/Board Member | |
Centre d'Immunologie Pierre Fabre | Corporate Officer/Principal | ||
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
SkylineDx BV
SkylineDx BV Medical/Nursing ServicesHealth Services SkylineDx BV develops molecular diagnostic tests for blood cancers. The firm focuses on the development and commercialization of gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. Its products include MMprofiler and AMLprofiler. The company was founded by Dharminder S. Chahal and Bob Löwenberg in 2005 and is headquartered in Rotterdam, the Netherlands. | Medical/Nursing Services | Director of Finance/CFO Director/Board Member | |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Biotechnology | Chairman | |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | Biotechnology | Director/Board Member | |
AEC Skyline Holding BV | Director/Board Member | ||
Evolvere Partners AB | Director/Board Member | ||
Orion Biotechnology Canada Ltd.
Orion Biotechnology Canada Ltd. BiotechnologyHealth Technology Orion Biotechnology Canada Ltd. operates as pharmaceutical company. The company was founded by Rudolf Bom in 2011 and is headquartered in Ottawa, Canada. | Biotechnology | Chairman | |
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member | |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Chairman | |
Stichting Op Klompen Begonnen | Investment Trusts/Mutual Funds | Director/Board Member | |
Stichting Start2Cure | Investment Trusts/Mutual Funds | Director/Board Member | |
de Hoben GmbH
de Hoben GmbH Real Estate DevelopmentFinance de Hoben GmbH is a private company that was founded in 2017 and engages in the buying and selling of land, buildings, and apartments. The company is based in Dusseldorf, Germany. | Real Estate Development | Director/Board Member | |
Campus Fraxinus Excelsior BV | Director/Board Member | ||
Ht Projecktentwicklung GmbH | Director/Board Member | ||
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Chairman |
Statistiche
Distribuzione geografica
Paesi Bassi | 11 |
Germania | 7 |
Stati Uniti | 6 |
Norvegia | 6 |
Svezia | 5 |
Settori
Health Technology | 20 |
Consumer Services | 10 |
Commercial Services | 7 |
Finance | 6 |
Miscellaneous | 4 |
Posizioni
Director/Board Member | 91 |
Corporate Officer/Principal | 26 |
Independent Dir/Board Member | 21 |
Chairman | 17 |
Doctorate Degree | 10 |
Contatti più connessi
Insiders | |
---|---|
Nanna Liebach Lüneborg | 29 |
Thomas O. Hecht | 24 |
Bernd Seizinger | 23 |
Vincent Ossipow | 22 |
Leonard Kruimer | 22 |
Erik Esveld | 15 |
Martin Welschof | 12 |
Andres McAllister | 9 |
Natalie Berner | 6 |
Cecilia Hofvander | 5 |
Sylvie Ryckebusch | 4 |
Ingunn Munch Lindvig | 4 |
Stefan Ericsson | 3 |
Kristoffer Bissessar | 3 |
Marie Moores | 2 |
- Borsa valori
- Insiders
- Emma Meurling
- Connessioni Società